Takeda's Sustainability Activities Receive Multiple Accolades by Rigorous ESG Evaluators

February 20, 2019

Sustainable Value Report 2018 receives “Merit Award” in 22nd Environmental Communication Awards
Awarded “Prime Status” for the second consecutive year by ISS-oekom Corporate Rating
Received “Industry Mover Sustainability Yearbook Award 2019” by RobecoSAM’s annual Corporate Sustainability Assessment

Osaka, Japan, February 20, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), today announced three major sustainability accolades. The company’s Sustainable Value Report (“SVR”) 2018 received a “Merit Award” in the Environmental Report Section of the 22nd Environmental Communication Awards, sponsored by Japan's Ministry of the Environment and the Global Environmental Forum. Takeda was also awarded “Prime Status” ISS-oekom Corporate Rating, certifying that the company fulfills ISS-oekom’s strict requirements regarding sustainability performance, and received “Industry Mover Sustainability Yearbook Award 2019” by RobecoSAM’s annual Corporate Sustainability Assessment (CSA). These accolades build on recognition by multiple indices for Takeda’s strong commitment to sustainability, in particular environmental management.

Takeda has received a total of six Environmental Communication Awards, which annually recognize communications activities that improve the quality of sustainability reporting including environmental information. SVR 2018 is recognized of its integrated reporting of rich environmental, social, and governance (ESG) data, such as global commitments to supplier management, 

reducing environmental impact throughout the value chain, human rights issues, and a holistic quality management system throughout the product lifecycle. Through proactive information disclosure as represented by this award, Takeda has received two additional recognitions from ESG evaluation agencies globally.

The sustainability rating ISS-oekom highly noted Takeda for Eco Efficiency, Climate Change Strategy, and Environmental Management. For the second consecutive year, Takeda achieved ISS-oekom Prime Status – received by only 12.3% of pharmaceutical and biotechnology companies evaluated. Prime companies rank among the leaders in their industry.

Additionally, Takeda received “Industry Mover Sustainability Yearbook Award 2019” by RobecoSAM’s annual CSA. Takeda has achieved the largest proportional improvement in its sustainability performance compared to the previous year in the pharmaceutical sector.


Takeda is selected in other benchmark ESG indices as below:

Name of Index/Investment Universe*/Ratings

Company/
Organization Conducting Assessment

Country

Honors Awarded

Global 100 Most Sustainable Corporations in the World Index

Corporate Knights

CND

4th consecutive year

Dow Jones Sustainability Asia Pacific Index

S&P Dow Jones Indices

US

9th consecutive year

FTSE4Good Developed Index

FTSE Russel

UK

14th consecutive year

Ethibel EXCELLENCE Investment Register

Forum Ethibel

BEL

From July 2017


As a pharmaceutical company dedicated to improving people’s lives, Takeda remains committed to fulfilling its social responsibilities in response to global needs.

About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR commitments, as well as how CSR priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit
https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com


Media Contacts:
Japanese Media                                                           
Kazumi Kobayashi                                                      
kazumi.kobayashi@takeda.com                                 
+81 (0) 3-3278-2095                                                   

Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933